Navigation Links
Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results
Date:9/14/2009

CHERRY HILL, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX) announces today that results from the Company's ongoing sponsored research studies indicate that Oraphyte(TM) can control nematode infestation pre-plant and post-plant in several species of turfgrass. In the coming months Nuvilex intends to initiate trials on golf course greens in the Southeastern United States under conditions that are most optimal for turfgrass growth. These commercial studies will determine and validate Oraphyte's usage requirements and application specifications. Nuvilex plans to register Oraphyte with the Environmental Protection Agency (EPA) in two phases: Nuvilex will first register Oraphyte(TM) with the EPA as a pesticide for use on terrestrial, non-food crops, followed by pesticide registration for use on high-value crops (e.g., terrestrial food crop use) such as soybeans and sugar cane.

From 2007 to 2009, renowned nematologist Edward McGawley, Ph.D. of the Louisiana State University Agricultural Center (LSU AgCenter) has investigated the use of Oraphyte(TM) as an all-natural nematocide for turfgrass. Initial greenhouse and Phase 1 microplot experiments conducted in 2007 and 2008 demonstrated that Oraphyte(TM) could control populations of nematodes in turfgrass; however, early formulations appeared to be phytotoxic.

From May to August 2009, Phase 2 microplot experiments conducted at the LSU AgCenter included the application of a new and improved Oraphyte(TM) formula to six nematode genera that were added to the soil of Agrostis stolonifera (Penn G2 Bentgrass) and Cynodon (Bermudagrass). Both species of turfgrass were grown in microplots in a controlled environment. Each microplot contained approximately 15-35 kg of soil and approximately 1.7 ft2 of turfgrass. Preliminary results showed that the new and improved formulations caused a statistically significant reduction
'/>"/>

SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula
2. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
3. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
4. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
5. Nuvilex, Inc. Announces Business Update Conference Call
6. Nuvilex, Inc. Announces Monthly Investor Conference Call
7. Nuvilex, Inc. Announces Investor Conference Call and Open House
8. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
9. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Today, Therapy Changes ... for Me?” The guide outlines common questions an individual ... addition to common types of groups an individual can ... from the interventions of the therapist, but also from ... group members,” says Rochelle Perper, Ph.D. and founder of ...
(Date:9/2/2014)... 02, 2014 The exciting information sessions ... professionals Carey Lewis and Bob Wiley. The ... those who have the desire to illuminate entertainment with ... performers could be invited to join the Bridge ... NC – Saturday, Sept. 6, Charlotte Convention Center, 501 ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... by helicopter, an expensive choice that may not impact patient ... and time is of the essence, helicopter transport is generally ... ground ambulance, but a paper published today in the online ... that the actual times to treatment for patients transported by ...
... HealthDay Reporter , WEDNESDAY, Oct. 12 (HealthDay ... for patients with a condition known as Barrett,s esophagus ... a large new Danish study suggests. Analyzing records ... determined that those with Barrett,s esophagus -- a disorder ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 12 ... marijuana run more than twice the risk of crashing compared to ... if the driver has also been drinking alcohol. The ... Reviews believe the findings are especially relevant in light of ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
... WEDNESDAY, Oct. 12 (HealthDay News) -- The death toll from ... risen to 23, and a total of 116 people have ... Control and Prevention reported late Wednesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
Cached Medicine News:Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Pot Smoking May More Than Double Crash Risk 2Health News:Pot Smoking May More Than Double Crash Risk 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2Health News:Death Toll From Cantaloupe-Linked Listeria Outbreak Now Stands at 23 2
(Date:9/2/2014)... DALLAS , September 2, 2014 ... Chromatography Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material ... Flash Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by ... Million in 2013. It is poised to grow at ... Million by 2018. Browse 90 market ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
... The Company's Aura-i Laser System is ... designed for office-based procedures. Its unique, integrated ... benign vascular, including telangiectasia on the leg ... leg veins. It can also be used ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: